Table of Contents
On Tuesday, British pharmaceutical giant GSK revealed that it is conducting a groundbreaking study involving more than 1 million older adults in the UK to explore whether its best-selling shingles vaccine, Shingrix, may help reduce the risk of dementia. This new research focuses on individuals aged 65 and 66, a group who have been part of a unique naturally randomized trial due to changes in the UK’s national vaccination program.
The study is leveraging the health data from around 1.4 million people, using a large database provided by the UK’s National Health Service (NHS). The key to this study is the natural experiment set up by a modification to the shingles vaccination program that expanded eligibility for the Shingrix vaccine to people aged 65 and over in 2023, whereas previously only those aged 70 and above were eligible. Those aged 66 to 69, however, were told they could not receive the vaccine until they turned 70, creating two distinct groups: one that received the vaccine and one that did not.
A Unique Data Set for Investigating the Link Between Shingles and Dementia
According to GSK’s Chief Scientific Officer Tony Wood, this shift in the vaccination program has effectively created a “naturally randomised trial” where people in similar age brackets have been randomly assigned to either receive the vaccine or not. This unique situation provides GSK with an unprecedented opportunity to study the potential relationship between the shingles vaccine and dementia risk in older adults.
While running a traditional clinical trial on such a large group would be prohibitively expensive, Wood pointed out that this partnership with the NHS allows GSK to conduct the study without the usual logistical and financial hurdles. This sets the stage for potentially groundbreaking insights into the link between vaccination and the prevention of dementia, a question that has been difficult to answer through conventional means.
Study to Focus on Dementia Prevention
GSK’s study will follow the health data of these individuals over the next few years, focusing particularly on whether the Shingrix vaccine lowers the risk of developing dementia, specifically Alzheimer’s disease. Research has already suggested a potential link between shingles vaccines and reduced dementia risk, though prior studies have only shown correlations, not causality. This new study, conducted in partnership with the UK Dementia Research Institute and Health Data Research UK, aims to investigate the connection more definitively.
Cholera Outbreak in Angola Claims 329 Lives
Wood emphasized that the study would track the health outcomes of individuals until they reach 70, the age when they would become eligible for the vaccine, while also accounting for other factors such as pre-existing medical conditions that could influence dementia risk. The study could potentially confirm whether the Shingrix vaccine plays a direct role in preventing dementia in older adults, which would be a significant finding for both the medical and pharmaceutical communities.
Potential for Expanded Vaccine Label
Should the study show a clear, causal relationship between Shingrix and a reduced risk of dementia, GSK could discuss the findings with regulatory authorities, including the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), in hopes of expanding the vaccine’s approved indications. Such a breakthrough could potentially lead to broader recommendations for the vaccine and could even set the stage for new treatment options for dementia.
More than 55 million people worldwide currently live with dementia, and Alzheimer’s disease is the most common form of the condition. While research into Alzheimer’s and other forms of dementia has seen numerous setbacks in the past, recent advancements in clinical trials, including those exploring Alzheimer’s vaccines, have offered hope for more effective treatments in the future.
A Step Forward in Dementia Research
If GSK’s study proves successful, it could represent a significant leap forward in dementia research, adding a new tool to the arsenal of preventive measures against cognitive decline. The investigation into whether an existing vaccine could have a preventive effect on dementia represents an exciting possibility in the field, given the overwhelming global need for effective treatments.
In the meantime, GSK and its partners will continue to explore the health data from the NHS database, examining whether the Shingrix vaccine can reduce the risk of dementia in older adults and, potentially, change the way we think about vaccine efficacy and disease prevention on a larger scale.
As the research progresses, the results could offer new insights into how the shingles vaccine might provide protection not just against shingles, but also against one of the most challenging and widespread conditions affecting aging populations worldwide.
